For example, the small molecule inhibitor 5-azacytidine, which targets the DNA methyltransferase DNMT3A, has been approved for clinical treatment of patients with acute lymphoblastic leukemia (AML) (3), and belinostat, which targets histone deacetylases (HDACs) in peripheral T-cell lymphoma (PTCL), was approved for use in 2014 (4). Here, DNMT3A is linked to acute myeloid leukemia.